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Abstract
Background: The prognosis of pancreatic cancer (PaC) strongly varies across different stages and age groups,
which has unfortunately not been well recorded in the literature. This international population-based study aimed
to provide tumor-node-metastasis (TNM) stage- and age-specific survival estimates and trends in resected and
overall (resected and unresected) PaC in the early twenty-first century.
Methods: Using data from the US Surveillance, Epidemiology, and End Results-18 Program and the national cancer
registries of the Netherlands, Belgium, Norway, and Slovenia, short-term and long-term overall survival results
stratified by TNM stage and age in resected and overall primary PaC, irrespective of being microscopically confirmed
or not, in 2003–2014 were computed using the Kaplan-Meier method. The temporal survival trends over three
predefined periods (2003–2005, 2006–2008, and 2009–2011) were further examined using the log-rank test.
Results: In total, data for 125,183 patients were analyzed. Overall, age-stratified 3-year survival was 20–34% (< 60 years),
14–25% (60–69 years), and 9–13% (≥ 70 years) in stages I–II PaC; and 2–5% (< 60 years), 1–2% (60–69 years), and
< 1–1% (≥ 70 years) in stages III–IV cancer. Patients who underwent operation had higher 3-year survival in each stage
and age group (stages I–II: 23–39% (< 60 years), 16–31% (60–69 years), and 17–30% (≥ 70 years); stages III–IV: 5–19%
(< 70 years) and 2–14% (≥ 70 years)). Perioperative survival also decreased with advancing stage and older age
(stages I–II: 98–100% (< 60 years), 97–99% (60–69 years), and 94–99% (≥ 70 years); stages III–IV: 94–99% (< 70 years) and
81–96% (≥ 70 years)). Between 2003 and 2005 and 2009–2011, for overall PaC, both short-term and long-term survival
improvements were observed in all countries except Belgium; for resected disease, short-term improvements were
present only in the USA and Slovenia, but long-term improvements were observed in all countries except Slovenia,
with stage-specific variations.
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Conclusions: Our large international study provides TNM stage- and age-specific population-based survival in overall
and resected PaC that will facilitate clinical counseling. While the survival expectations for patients with resected PaC are
substantially higher than the widely available and known dismal survival predictions for overall patients, conclusions on
the benefits of resection cannot be made from this observational study. Patients with advanced-stage disease and/or
older age should undergo careful risk assessment before treatment. Limited but inspiring improvement in survival
is observed.
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Background
Pancreatic cancer (PaC) is one of the deadliest malignan-
cies worldwide; > 340,000 individuals receive this diag-
nosis annually with similar incidence and mortality rates
[1]. PaC incidence is especially high in developed coun-
tries, being the fourth leading cause of cancer-related
deaths in Western societies [2]. In the EU, PaC incidence
has been stable or moderately increasing over the past de-
cades, and it was estimated to have caused 91,500 deaths
in 2017 and to cause 111,500 deaths in 2025, potentially
becoming the third leading cause of cancer death [3].
The prognosis for PaC is poor, with 5-year survival of
only ~ 5% [4]. Due to lack of effective early screening
methods, more than half of PaCs are detected at ad-
vanced stages and are treated largely palliatively [5, 6].
According to the current guidelines [7–11], only tumor-
node-metastasis (TNM) stages I–II PaCs are usually re-
sectable, although the resectability criteria are differen-
tially and arguably defined [12]. While resection could
markedly improve the long-term survival in selected pa-
tients, less than one-fifth of diagnosed cases are consid-
ered eligible for resection [5, 10]. Patients with resectable
PaC who undergo resection have much better survival
rates than those who cannot undergo resection [8, 10].
We previously described the low and varying resection
rates for PaC in Europe and the USA [13]. When coun-
seling PaC patients who are considering surgery or who
have already undergone resection, it is important to pro-
vide survival estimates for the resected subgroup. How-
ever, at this time, population-based survival estimates
are only available for overall patients without differenti-
ation by resection or TNM stage [4], according to which,
however, survival might vary greatly. Survival odds in
resected PaC data from institutional reports would be ac-
companied with relatively high patient selection, making
the generalizability questionable. Based on multiple na-
tional databases, this large investigation aimed to compre-
hensively and robustly provide 1-month to 5-year overall
survival estimates at the population level for overall
(resected and unresected) and resected PaC patients diag-
nosed in the early twenty-first century in Europe and the
USA stratified by TNM stage and age. Furthermore, sur-
vival trends over time in each country were explored.
Methods
Study design
A list of all contacted cancer registries together with rea-
sons for exclusion are provided in Additional file 1:
Table S1. Population-based PaC data from the US Sur-
veillance, Epidemiology, and End Results (SEER)-18 Pro-
gram, the Netherlands Cancer Registry, the Belgian
Cancer Registry, the Cancer Registry of Norway, and the
Cancer Registry of Slovenia were investigated in this
large real-world observational study (Additional file 1:
Table S2). The data quality of each registry was described
in a previous publication [13], focusing on resection rates
only. Among the previous participants [13], the Danish
registry withdrew its participation due to some legislation
issues, and the small population size for resected patients
in Estonia did not allow for reasonable survival analyses.
Institution-based data were not included due to the rela-
tively high risk of patient selection bias. The participating
European national registries, located in western, northern,
and southern Europe, respectively, were those able to pro-
vide data of relatively high quality, according to a uniform
data-request sheet, to ensure the robustness of the results.
All variables were uniformly (re)coded across registries.
National population-based registries were not included if
they were not able to provide eligible treatment, TNM sta-
ging, or survival data. This study was approved by the
Ethics Committee of Medical Faculty Heidelberg and re-
ported following the Strengthening the Reporting of Ob-
servational Studies in Epidemiology (STROBE) guidelines.
Patients
Only patients with pathologic and/or clinical diagnoses
of invasive primary malignant tumors of the exocrine
pancreas were included. Patients were included irre-
spective of being microscopically diagnosed or not in
this real-world study on survival for resected and overall
PaC following the EUROCARE studies [4, 14], since
consensus has been reached by the International Study
Group of Pancreatic Surgery (ISGPS) that, in the pres-
ence of a solid mass suspicious for malignancy, biopsy
proof has not been and is not required before proceeding
with resection [15]. Those with benign/premalignant tu-
mors, non-pancreatic neoplasms involving the pancreas,
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neuroendocrine tumors, carcinoids, sarcomas/stromal tu-
mors, germ cell neoplasms, lymphomas, or periampullar
tumors (Additional file 1: Table S3), with diagnosis
based on autopsy or death certificate only, or with un-
known diagnosis/follow-up date or survival status were
excluded. Patients without TNM staging were also ex-
cluded. As the fifth edition of the TNM staging system
was incompatible with the later versions in effect
during 2003–2017 [8], only patients with PaC diagnosed
after 2002 were included.
Collected information
Information on patient (year of diagnosis, sex, and age)
and tumor characteristics (microscopic confirmation,
TNM stage, location, and differentiation), treatment (re-
section, (neo) adjuvant chemotherapy, and radiotherapy),
follow-up, and survival status was obtained. Tumor
morphology and topography were coded according to
the International Classification of Diseases for Oncology,
Third Edition. Tumor stage was based on the TNM sta-
ging system, sixth/seventh edition [8]. In stage classifi-
cation, pathologic (pTNM) stages were prioritized over
clinical (cTNM) ones. Resection was defined as surgical
removal of the primary tumor, regardless of being
curative or palliative. Survival status was obtained from
official population registers and/or national death
registrations.
Outcome measures
Short-term (1-month to 6-month) and relatively long-term
(1-year to 5-year) survival data in overall and resected PaC
stratified by TNM stage (I–II and III–IV) and age group
(< 60, 60–69, and ≥ 70 years) were presented. Cancer stage
was divided into stages I–II and III–IV, considering the
former to be clearly resectable and the latter mostly unre-
sectable, and to ensure an adequate number for assessment
in each subgroup. When describing survival for resected
stages III–IV PaC, the subgroups < 60 and 60–69 years
were combined considering the small size of either. Sur-
vival trends over 3 calendar years (2003–2005, 2006–2008,
and 2009–2011) in each country were further reported. All
these categories were predefined.
Statistical analyses
Complete-case analysis was performed for patients with
known TNM stages. Results were described for each
country separately without pooling, considering the po-
tential heterogeneity across countries. Overall survival
was defined as the months between diagnosis and death
from any cause/last follow-up, and was estimated for
overall and resected PaC patients by TNM stage and age
group using the Kaplan-Meier method, with the 1-, 3-,
6-, 12-, 24-, 36-, and 60-month survival rates calculated.
Sensitivity analyses were conducted by limiting the
overall patients to those with microscopic confirmation.
Changes in survival rates of overall and operated pa-
tients diagnosed between 2003 and 2005 and 2009–2011
were examined using the log-rank test. Statistical signifi-
cance was defined by two-sided P < 0.05. The SAS soft-
ware (version 9.4, Cary, NC, USA) was used.
Results
Patient characteristics
In total, data for 125,183 patients (stages I–II, 42,955
(34%); stages III–IV, 82,228 (66%)) were analyzed. Pa-
tients were diagnosed in comparable periods in all coun-
tries (2003/2004 until 2013/2014). Demographic and
clinical characteristics for overall and operated patients
with stages I–II and III–IV PaCs are shown in Table 1
and described in Additional file 1. In overall PaCs, 66%
(Norway) to 91% (Belgium) of stages I–II cancers and 53%
(Slovenia) to 86% (Belgium) of stages III–IV cancers were
microscopically confirmed. Nearly all resected PaCs were
microscopically confirmed (stages I–II, 99– ≥ 99%; stages
III–IV, 92–100%).
Survival in overall and resected stages I–II PaCs
Survival in overall and resected stages I–II tumors is
shown in Fig. 1, and the corresponding 1-month to 5-year
survival rates are detailed in Table 2. For total patients, sur-
vival was lower in older patients and decreased strongly
after diagnosis, with 3-year rates of 20–34% (< 60 years),
14–25% (60–69 years), and 9–13% (≥ 70 years), respect-
ively. The subgroup of resected patients of all age groups
in all countries had higher survival estimates, with
1-month (perioperative) rates of 98–100% (< 60 years),
97–99% (60–69 years), and 94–99% (≥ 70 years); and
3-year rates of 23–39% (< 60 years), 16–31% (60–69 years),
and 17–30% (≥ 70 years), respectively. Again, younger pa-
tients had a better prognosis than older ones. However,
age-specific differences were smaller, especially between
those aged 60–69 and ≥ 70 years.
Survival in overall and resected stages III–IV PaCs
Considering the potentially varying proportions of un-
derreporting of advanced-stage disease, survival results
for stages III–IV PaCs should be interpreted with cau-
tion. Survival in overall and resected stages III–IV can-
cers is shown in Additional file 1: Figure S1, and the
corresponding 1-month to 5-year survival rates are de-
tailed in Additional file 1: Table S4. Generally, patients
with stages III–IV PaCs had much lower survival results
than those with stages I–II tumors, and already had
high mortality shortly after diagnosis. In the total
group, survival decreased with increasing age, with
3-year rates of 2–5% (< 60 years), 1–2% (60–69 years),
and 1–1% (≥ 70 years), respectively. The resected sub-
groups showed higher survival estimates than the
Huang et al. BMC Medicine  (2018) 16:125 Page 3 of 15
Ta
b
le
1
D
em
og
ra
ph
ic
an
d
cl
in
ic
al
ch
ar
ac
te
ris
tic
s
of
pa
tie
nt
s
w
ith
st
ag
es
I–
II
an
d
III
–I
V
pa
nc
re
at
ic
ca
nc
er
Pa
ra
m
et
er
U
SA
(2
00
4–
20
13
)
Th
e
N
et
he
rla
nd
s
(2
00
3–
20
14
)
Be
lg
iu
m
(2
00
4–
20
13
)
N
or
w
ay
(2
00
3–
20
14
)
Sl
ov
en
ia
(2
00
3–
20
13
)
G
ro
up
O
ve
ra
ll
Re
se
ct
ed
O
ve
ra
ll
Re
se
ct
ed
O
ve
ra
ll
Re
se
ct
ed
O
ve
ra
ll
Re
se
ct
ed
O
ve
ra
ll
Re
se
ct
ed
St
ag
es
I–
II
N
um
be
r
(n
)
31
,3
13
13
,3
03
(4
3)
57
10
26
75
(4
7)
34
37
21
55
(6
3)
15
45
52
6
(3
4)
66
7
40
6
(6
1)
M
ic
ro
sc
op
ic
al
ly
co
nf
irm
ed
27
,2
90
(8
7)
13
,2
90
(>
99
)
40
46
(7
1)
26
73
(>
99
)
31
27
(9
1)
21
48
(>
99
)
10
17
(6
6)
52
0
(9
9)
47
5
(7
1)
40
1
(9
9)
G
en
de
r,
fe
m
al
e
16
,1
93
(5
2)
66
04
(5
0)
29
51
(5
2)
12
68
(4
7)
16
84
(4
9)
99
3
(4
6)
85
3
(5
5)
26
1
(5
0)
36
1
(5
4)
20
9
(5
2)
A
ge
,y
ea
rs
70
±
12
66
±
11
71
±
11
65
±
10
69
±
11
66
±
10
72
±
12
65
±
11
69
±
11
65
±
10
A
ge
gr
ou
p
<
60
ye
ar
s
61
00
(2
0)
35
74
(2
7)
98
1
(1
7)
69
3
(2
6)
68
6
(2
0)
54
6
(2
5)
23
4
(1
5)
13
4
(2
6)
14
4
(2
2)
12
2
(3
0)
60
–6
9
ye
ar
s
78
17
(2
5)
42
72
(3
2)
14
77
(2
6)
97
8
(3
7)
93
7
(2
7)
69
8
(3
2)
37
5
(2
4)
19
5
(3
7)
16
6
(2
5)
13
1
(3
2)
≥
70
ye
ar
s
17
,3
96
(5
6)
54
57
(4
1)
32
52
(5
7)
10
04
(3
8)
18
14
(5
3)
91
1
(4
2)
93
6
(6
1)
19
7
(3
7)
35
7
(5
4)
15
3
(3
8)
Tu
m
or
lo
ca
tio
na
Pa
nc
re
as
he
ad
22
,4
12
(8
3)
95
73
(8
0)
46
66
(8
9)
21
87
(8
9)
18
07
(8
1)
12
07
(8
2)
85
1
(8
5)
39
4
(8
4)
47
1
(8
8)
32
1
(8
7)
Pa
nc
re
as
bo
dy
25
02
(9
)
89
0
(8
)
25
5
(5
)
91
(4
)
17
9
(8
)
10
0
(7
)
87
(9
)
33
(7
)
35
(7
)
26
(7
)
Pa
nc
re
as
ta
il
21
96
(8
)
14
48
(1
2)
29
6
(6
)
19
1
(8
)
24
4
(1
1)
16
9
(1
1)
62
(6
)
41
(9
)
32
(6
)
21
(6
)
O
th
er
42
03
(1
3)
13
92
(1
1)
49
3
(9
)
20
6
(8
)
12
07
(3
5)
67
9
(3
2)
54
5
(3
5)
58
(1
1)
12
9
(1
9)
38
(9
)
D
iff
er
en
tia
tio
nb
W
el
l
21
45
(1
3)
14
28
(1
2)
28
3
(1
2)
24
4
(1
1)
38
9
(1
8)
30
2
(1
7)
61
(1
0)
27
(6
)
41
(1
0)
37
(1
0)
In
te
rm
ed
ia
te
75
74
(4
7)
60
26
(5
1)
12
25
(5
1)
11
38
(5
2)
10
72
(4
8)
90
1
(5
0)
35
2
(5
5)
25
9
(6
1)
15
3
(3
7)
14
2
(3
8)
Po
or
/u
nd
iff
er
en
tia
te
d
62
64
(3
9)
44
64
(3
8)
92
0
(3
8)
80
2
(3
7)
76
2
(3
4)
60
8
(3
4)
22
3
(3
5)
13
5
(3
2)
22
1
(5
3)
19
2
(5
2)
N
eo
ad
ju
va
nt
ch
em
ot
he
ra
py
–
N
A
–
50
(2
)
–
53
(3
)
–
N
A
–
2
(1
)
N
eo
ad
ju
va
nt
ra
di
ot
he
ra
py
–
52
2
(4
)
–
34
(1
)
–
20
(1
)
–
0
(0
)
–
1
(<
1)
Re
se
ct
io
n
ty
pe
Pa
nc
re
at
od
uo
de
ne
ct
om
y
–
94
79
(7
1)
–
22
69
(8
5)
–
N
A
–
N
A
–
N
A
D
is
ta
lp
an
cr
ea
te
ct
om
y
–
18
78
(1
4)
–
25
6
(1
0)
–
N
A
–
N
A
–
N
A
To
ta
lp
an
cr
ea
te
ct
om
y
–
16
29
(1
2)
–
42
(2
)
–
N
A
–
N
A
–
N
A
O
th
er
c
–
31
4
(2
)
–
10
8
(4
)
–
N
A
–
N
A
–
N
A
A
dj
uv
an
t/
pa
lli
at
iv
e
ch
em
ot
he
ra
py
N
A
N
A
13
92
(2
4)
10
78
(4
0)
17
96
(5
2)
12
00
(5
6)
26
5
(1
7)
12
7
(2
4)
13
1
(2
0)
12
0
(3
0)
A
dj
uv
an
t/
pa
lli
at
iv
e
ra
di
ot
he
ra
py
44
60
(1
4)
41
93
(3
2)
12
0
(2
)
33
(1
)
32
6
(1
0)
19
0
(9
)
64
(4
)
17
(3
)
9
(1
)
8
(2
)
St
ag
es
III
–I
V
N
um
be
r
(n
)
55
,1
53
19
98
(4
)
13
,9
74
23
7
(2
)
56
32
29
8
(5
)
46
33
10
8
(2
)
19
97
13
5
(7
)
M
ic
ro
sc
op
ic
al
ly
co
nf
irm
ed
46
,9
73
(8
5)
19
94
(>
99
)
10
,3
75
(7
4)
23
7
(1
00
)
48
37
(8
6)
29
7
(>
99
)
32
24
(7
0)
10
5
(9
7)
10
56
(5
3)
12
4
(9
2)
G
en
de
r,
fe
m
al
e
26
,4
27
(4
8)
96
9
(4
9)
67
55
(4
8)
10
6
(4
5)
27
00
(4
8)
15
4
(5
2)
23
32
(5
0)
47
(4
4)
96
7
(4
8)
56
(4
2)
A
ge
,y
ea
rs
69
±
12
65
±
12
68
±
11
64
±
10
69
±
11
64
±
10
71
±
12
64
±
10
69
±
11
65
±
10
Huang et al. BMC Medicine  (2018) 16:125 Page 4 of 15
Ta
b
le
1
D
em
og
ra
ph
ic
an
d
cl
in
ic
al
ch
ar
ac
te
ris
tic
s
of
pa
tie
nt
s
w
ith
st
ag
es
I–
II
an
d
III
–I
V
pa
nc
re
at
ic
ca
nc
er
(C
on
tin
ue
d)
Pa
ra
m
et
er
U
SA
(2
00
4–
20
13
)
Th
e
N
et
he
rla
nd
s
(2
00
3–
20
14
)
Be
lg
iu
m
(2
00
4–
20
13
)
N
or
w
ay
(2
00
3–
20
14
)
Sl
ov
en
ia
(2
00
3–
20
13
)
G
ro
up
O
ve
ra
ll
Re
se
ct
ed
O
ve
ra
ll
Re
se
ct
ed
O
ve
ra
ll
Re
se
ct
ed
O
ve
ra
ll
Re
se
ct
ed
O
ve
ra
ll
Re
se
ct
ed
A
ge
gr
ou
p
<
60
ye
ar
s
12
,5
82
(2
3)
63
6
(3
2)
29
38
(2
1)
69
(2
9)
10
43
(1
9)
92
(3
1)
75
9
(1
6)
32
(3
0)
39
3
(2
0)
40
(3
0)
60
–6
9
ye
ar
s
15
,0
81
(2
7)
62
2
(3
1)
44
12
(3
2)
96
(4
1)
16
08
(2
9)
10
3
(3
5)
12
68
(2
7)
43
(4
0)
51
3
(2
6)
45
(3
3)
≥
70
ye
ar
s
27
,4
90
(5
0)
74
0
(3
7)
66
24
(4
7)
72
(3
0)
29
81
(5
3)
10
3
(3
5)
26
06
(5
6)
26
(2
4)
10
91
(5
5)
43
(3
2)
Tu
m
or
lo
ca
tio
na
Pa
nc
re
as
he
ad
21
,2
44
(5
6)
10
69
(6
6)
72
02
(6
2)
16
6
(7
9)
15
85
(5
8)
12
6
(6
9)
12
45
(6
3)
57
(6
6)
65
3
(6
4)
80
(7
8)
Pa
nc
re
as
bo
dy
78
93
(2
1)
16
8
(1
0)
18
44
(1
6)
11
(5
)
50
8
(1
9)
19
(1
0)
34
0
(1
7)
8
(9
)
16
0
(1
6)
12
(1
2)
Pa
nc
re
as
ta
il
90
03
(2
4)
38
1
(2
4)
26
66
(2
3)
34
(1
6)
64
9
(2
4)
37
(2
0)
38
2
(1
9)
21
(2
4)
21
5
(2
1)
10
(1
0)
O
th
er
17
,0
13
(3
1)
38
0
(1
9)
22
62
(1
6)
26
(1
1)
28
90
(5
1)
11
6
(3
9)
26
66
(5
8)
22
(2
0)
96
9
(4
9)
33
(2
4)
D
iff
er
en
tia
tio
nd
W
el
l
12
13
(1
0)
17
3
(1
1)
22
2
(9
)
20
(1
1)
42
5
(1
7)
42
(1
7)
12
2
(8
)
6
(7
)
33
(8
)
6
(7
)
In
te
rm
ed
ia
te
45
18
(3
5)
68
0
(4
5)
83
3
(3
5)
98
(5
1)
96
2
(3
9)
11
3
(4
7)
59
6
(4
0)
50
(6
1)
11
2
(2
5)
30
(3
4)
Po
or
/u
nd
iff
er
en
tia
te
d
67
95
(5
6)
67
0
(4
4)
13
40
(5
6)
73
(3
8)
10
82
(4
4)
88
(3
6)
76
5
(5
2)
26
(3
2)
29
7
(6
7)
52
(5
9)
N
eo
ad
ju
va
nt
ch
em
ot
he
ra
py
–
N
A
–
15
(6
)
–
24
(8
)
–
N
A
–
0
(0
)
N
eo
ad
ju
va
nt
ra
di
ot
he
ra
py
–
13
9
(7
)
–
5
(2
)
–
9
(3
)
–
0
(0
)
–
0
(0
)
Re
se
ct
io
n
ty
pe
Pa
nc
re
at
od
uo
de
ne
ct
om
y
–
11
40
(5
7)
–
17
8
(7
5)
–
N
A
–
N
A
–
N
A
D
is
ta
lp
an
cr
ea
te
ct
om
y
–
29
5
(1
5)
–
39
(1
7)
–
N
A
–
N
A
–
N
A
To
ta
lp
an
cr
ea
te
ct
om
y
–
21
1
(1
1)
–
5
(2
)
–
N
A
–
N
A
–
N
A
O
th
er
c
–
35
2
(1
8)
–
15
(6
)
–
N
A
–
N
A
–
N
A
A
dj
uv
an
t/
pa
lli
at
iv
e
ch
em
ot
he
ra
py
N
A
N
A
34
75
(2
5)
81
(3
4)
36
61
(6
5)
19
5
(6
5)
11
59
(2
5)
25
(2
3)
36
8
(1
8)
39
(2
9)
A
dj
uv
an
t/
pa
lli
at
iv
e
ra
di
ot
he
ra
py
77
0
(1
)
38
3
(1
9)
32
8
(2
)
7
(3
)
35
8
(6
)
35
(1
2)
19
8
(4
)
4
(4
)
46
(2
)
5
(4
)
N
O
S
no
t
ot
he
rw
is
e
sp
ec
ifi
ed
,N
A
no
t
av
ai
la
bl
e;
−
,n
ot
ap
pl
ic
ab
le
En
um
er
at
io
n
da
ta
ar
e
sh
ow
n
as
co
un
t
(p
er
ce
nt
ag
e
[%
]),
an
d
m
ea
su
re
m
en
t
da
ta
as
m
ea
n
±
st
an
da
rd
de
vi
at
io
n.
Re
co
rd
s
ar
e
co
m
pl
et
e,
ot
he
rw
is
e
sp
ec
ifi
ed
be
lo
w
a T
he
pe
rc
en
ta
ge
s
of
pa
nc
re
as
he
ad
,b
od
y,
an
d
ta
il
ar
e
th
e
pr
op
or
tio
ns
co
m
pa
re
d
to
th
e
to
ta
lt
um
or
ca
se
s
of
th
e
3
lo
ca
tio
ns
;”
ot
he
r”
in
cl
ud
es
pa
nc
re
as
du
ct
,o
ve
rla
pp
in
g
le
si
on
,N
O
S,
an
d
ot
he
r
sp
ec
ifi
ed
pa
rt
s,
an
d
its
pr
op
or
tio
n
is
re
la
tiv
e
to
th
e
w
ho
le
ca
se
s
b
U
nk
no
w
n
di
ff
er
en
tia
tio
n
in
st
ag
es
I–
II
ca
nc
er
:U
SA
,o
ve
ra
ll
15
,3
30
(4
9%
),
re
se
ct
ed
13
85
(1
0%
);
th
e
N
et
he
rla
nd
s,
ov
er
al
l3
28
2
(5
8%
),
re
se
ct
ed
49
1
(1
8%
);
Be
lg
iu
m
,o
ve
ra
ll
12
14
(3
5%
),
re
se
ct
ed
34
4
(1
6%
);
N
or
w
ay
,o
ve
ra
ll
90
9
(5
9%
),
re
se
ct
ed
10
0
(1
9%
);
Sl
ov
en
ia
,o
ve
ra
ll
25
2
(3
8%
),
re
se
ct
ed
35
(9
%
);
Es
to
ni
a,
ov
er
al
l1
34
(4
7%
),
re
se
ct
ed
32
(2
0%
)
c P
an
cr
ea
te
ct
om
y
(N
O
S)
an
d
lo
ca
lr
es
ec
tio
n
d
U
nk
no
w
n
di
ff
er
en
tia
tio
n
in
st
ag
es
III
–I
V
ca
nc
er
:U
SA
,o
ve
ra
ll
42
,6
27
(7
7%
),
re
se
ct
ed
47
5
(2
4%
);
th
e
N
et
he
rla
nd
s,
ov
er
al
l1
1,
57
9
(8
3%
),
re
se
ct
ed
46
(1
9%
);
Be
lg
iu
m
,o
ve
ra
ll
31
63
(5
6%
),
re
se
ct
ed
55
(1
9%
);
N
or
w
ay
,o
ve
ra
ll
31
50
(6
8%
),
re
se
ct
ed
26
(2
4%
);
Sl
ov
en
ia
,o
ve
ra
ll
15
55
(7
8%
),
re
se
ct
ed
47
(3
5%
);
Es
to
ni
a,
ov
er
al
l7
18
(8
6%
),
re
se
ct
ed
5
(2
8%
)
Huang et al. BMC Medicine  (2018) 16:125 Page 5 of 15
overall population in all countries and all age groups
(perioperative rates: < 70 years, 94–99%; ≥ 70 years, 81–
96%; 3-year rates: < 70 years, 5–19%; ≥ 70 years, 2–14%).
Differences between age groups were smaller in the
resected subgroups than the overall patient population.
Survival in overall stages I–II and III–IV PaCs with
microscopic confirmation
Considering the relatively high proportions of non-
microscopically confirmed overall PaC patients, we con-
ducted sensitivity analyses by limiting the patients with
Fig. 1 Kaplan-Meier curves (solid lines) of age group-specific survival in overall (upper panel) and resected patients (lower panel) with TNM stages
I–II pancreatic cancers. The dashed lines indicate the 95% confidence limits, and the shadows represent the Hall-Wellner confidence bands. Numbers of
patients at risk are also reported. Median survival is in months. IQR interquartile range
Huang et al. BMC Medicine  (2018) 16:125 Page 6 of 15
Ta
b
le
2
U
na
dj
us
te
d
su
rv
iv
al
pr
op
or
tio
ns
in
pa
tie
nt
s
w
ith
ov
er
al
la
nd
re
se
ct
ed
st
ag
es
I–
II
pa
nc
re
at
ic
ca
nc
er
Ti
m
e
U
SA
Th
e
N
et
he
rla
nd
s
Be
lg
iu
m
N
or
w
ay
Sl
ov
en
ia
O
ve
ra
ll
Re
se
ct
ed
O
ve
ra
ll
Re
se
ct
ed
O
ve
ra
ll
Re
se
ct
ed
O
ve
ra
ll
Re
se
ct
ed
O
ve
ra
ll
Re
se
ct
ed
O
S
(9
5%
C
I)a
O
S
(9
5%
C
I)
O
S
(9
5%
C
I)
O
S
(9
5%
C
I)
O
S
(9
5%
C
I)
O
S
(9
5%
C
I)
O
S
(9
5%
C
I)
O
S
(9
5%
C
I)
O
S
(9
5%
C
I)
O
S
(9
5%
C
I)
1
m
on
th
<
60
ye
ar
s
95
(9
4–
95
)
98
(9
8–
99
)
97
(9
6–
98
)
98
(9
7–
99
)
98
(9
7–
99
)
99
(9
7–
99
)
98
(9
6–
99
)
10
0
(1
00
–1
00
)
97
(9
3–
99
)
98
(9
3–
99
)
60
–6
9
ye
ar
s
92
(9
1–
93
)
97
(9
6–
97
)
95
(9
4–
96
)
97
(9
6–
98
)
97
(9
6–
98
)
98
(9
7–
99
)
97
(9
4–
98
)
99
(9
5–
10
0)
96
(9
2–
98
)
99
(9
4–
10
0)
≥
70
ye
ar
s
79
(7
8–
79
)
94
(9
3–
94
)
88
(8
7–
89
)
96
(9
5–
97
)
93
(9
2–
94
)
96
(9
4–
97
)
89
(8
6–
90
)
99
(9
5–
10
0)
85
(8
1–
89
)
99
(9
5–
10
0)
3
m
on
th
s
<
60
ye
ar
s
89
(8
8–
90
)
96
(9
5–
97
)
92
(9
0–
94
)
97
(9
5–
98
)
95
(9
3–
96
)
96
(9
4–
98
)
95
(9
2–
97
)
99
(9
5–
10
0)
92
(8
6–
95
)
94
(8
8–
97
)
60
–6
9
ye
ar
s
84
(8
4–
85
)
94
(9
3–
95
)
87
(8
5–
89
)
94
(9
3–
96
)
93
(9
1 –
94
)
94
(9
2–
96
)
90
(8
6–
93
)
97
(9
3–
99
)
90
(8
4–
94
)
96
(9
1–
98
)
≥
70
ye
ar
s
65
(6
4–
66
)
89
(8
8–
90
)
72
(7
0–
73
)
91
(8
9–
92
)
83
(8
1–
84
)
90
(8
8–
92
)
68
(6
5–
71
)
95
(9
1–
98
)
66
(6
1–
71
)
88
(8
2–
92
)
6
m
on
th
s
<
60
ye
ar
s
80
(7
9–
81
)
91
(9
0–
92
)
81
(7
8–
83
)
92
(9
0–
94
)
90
(8
7–
92
)
93
(9
0–
95
)
86
(8
1–
90
)
96
(9
0–
98
)
88
(8
1–
92
)
89
(8
2–
94
)
60
–6
9
ye
ar
s
73
(7
2–
74
)
88
(8
6–
89
)
76
(7
4–
78
)
89
(8
6–
91
)
86
(8
3–
88
)
89
(8
7–
91
)
77
(7
2–
81
)
91
(8
6–
95
)
78
(7
1–
84
)
85
(7
7–
90
)
≥
70
ye
ar
s
51
(5
0–
51
)
80
(7
9–
81
)
53
(5
1–
55
)
81
(7
8–
83
)
67
(6
5–
69
)
80
(7
7–
83
)
50
(4
7–
53
)
88
(8
3–
92
)
50
(4
5–
55
)
82
(7
5–
88
)
12
m
on
th
s
<
60
ye
ar
s
59
(5
7–
60
)
75
(7
3–
76
)
60
(5
6–
63
)
74
(7
0–
77
)
73
(7
0–
76
)
78
(7
5–
82
)
64
(5
7–
70
)
82
(7
5–
88
)
60
(5
2–
68
)
63
(5
4–
71
)
60
–6
9
ye
ar
s
52
(5
1–
53
)
71
(6
9–
72
)
53
(5
0–
55
)
68
(6
5–
71
)
65
(6
2–
68
)
72
(6
8–
75
)
52
(4
7–
57
)
73
(6
6–
79
)
55
(4
8–
63
)
62
(5
3–
70
)
≥
70
ye
ar
s
31
(3
1–
32
)
61
(5
9–
62
)
30
(2
9–
32
)
61
(5
7–
64
)
43
(4
0–
45
)
58
(5
5–
62
)
28
(2
5–
31
)
70
(6
3–
76
)
31
(2
6–
36
)
60
(5
1–
67
)
24
m
on
th
s
<
60
ye
ar
s
35
(3
4–
37
)
50
(4
8–
52
)
30
(2
7–
33
)
40
(3
6–
44
)
47
(4
3–
51
)
53
(4
9–
57
)
38
(3
2–
45
)
58
(4
8–
66
)
33
(2
5–
41
)
36
(2
7–
44
)
60
–6
9
ye
ar
s
29
(2
8–
30
)
44
(4
2–
45
)
28
(2
5–
30
)
38
(3
5–
42
)
38
(3
5–
41
)
45
(4
1–
48
)
29
(2
4–
34
)
48
(4
0–
55
)
23
(1
7–
30
)
28
(2
0–
35
)
≥
70
ye
ar
s
16
(1
5–
16
)
37
(3
5–
38
)
14
(1
3–
15
)
33
(3
0–
37
)
21
(1
9–
23
)
33
(3
0–
36
)
13
(1
0–
15
)
38
(3
1–
45
)
16
(1
2–
20
)
30
(2
3–
37
)
36
m
on
th
s
<
60
ye
ar
s
26
(2
4–
27
)
37
(3
6–
39
)
20
(1
8–
23
)
27
(2
4–
31
)
34
(3
0–
37
)
39
(3
5–
43
)
26
(2
0–
32
)
39
(3
0–
48
)
22
(1
6–
29
)
23
(1
6–
31
)
60
–6
9
ye
ar
s
20
(1
9–
21
)
31
(2
9–
32
)
18
(1
6–
20
)
25
(2
2–
28
)
25
(2
2–
28
)
30
(2
7–
34
)
18
(1
4–
23
)
31
(2
4–
38
)
14
(9
–1
9)
16
(1
1–
23
)
≥
70
ye
ar
s
10
(1
0–
11
)
26
(2
4–
27
)
9
(8
–1
1)
24
(2
1–
27
)
13
(1
1–
14
)
21
(1
9–
24
)
9
(7
–1
1)
30
(2
3–
37
)
9
(7
–1
3)
17
(1
1–
23
)
60
m
on
th
s
<
60
ye
ar
s
19
(1
8–
20
)
28
(2
6–
30
)
14
(1
2–
17
)
19
(1
6–
23
)
23
(1
9–
26
)
26
(2
2–
30
)
17
(1
2–
23
)
25
(1
7–
34
)
15
(9
–2
1)
15
(9
–2
3)
60
–6
9
ye
ar
s
13
(1
2–
14
)
21
(2
0–
23
)
11
(9
–1
3)
16
(1
3–
19
)
16
(1
4–
19
)
20
(1
7–
23
)
13
(9
–1
7)
23
(1
6–
30
)
8
(5
–1
3)
10
(5
–1
6)
≥
70
ye
ar
s
6
(6
–7
)
16
(1
5–
17
)
5
(4
–6
)
13
(1
0–
16
)
7
(6
–8
)
12
(1
0–
15
)
6
(4
–7
)
17
(1
1–
24
)
5
(3
–8
)
10
(6
–1
6)
O
S
ov
er
al
ls
ur
vi
va
l,
CI
co
nf
id
en
ce
in
te
rv
al
a D
at
a
ar
e
sh
ow
n
as
su
rv
iv
al
pr
op
or
tio
n
(9
5%
co
nf
id
en
ce
in
te
rv
al
)
[%
]
Huang et al. BMC Medicine  (2018) 16:125 Page 7 of 15
overall stages I–II and III–IV cancer to those with
microscopic confirmation (Table 3 and Additional file 1:
Figure S2). Microscopically confirmed patients with
stages I–II and III–IV cancer generally had higher sur-
vival especially in those ≥ 70 years old and within
24 months after diagnosis, in all participating countries
except Belgium, where microscopic confirmation rates
were high and where survival remained very similar. The
3-year survival rates remained mostly similar to those of
the main analyses, and were 21–34% (< 60 years), 14–25%
(60–69 years), and 12–14% (≥ 70 years) in stages I–II PaC,
and 2–5% (< 60 years), 1–2% (60–69 years), and 1%–1%
(≥ 70 years) in stages III–IV cancer.
Temporal survival trends in overall and resected PaCs
by stage
Trends in 1-month to 5-year survival of patients diag-
nosed in 2003–2005, 2006–2008, and 2009–2011 are
shown in Table 4 and Additional file 1: Figures S3–S7.
Significant survival changes between 2003 and 2005 and
2009–2011 are detailed below.
Short-term survival
Significant increases in 1-month survival for overall PaC
patients were observed in the USA and the Netherlands,
with 3 and 3% units increase (UI) for stage I–II and 2
and 3 UI for stages III–IV tumors. In Slovenia, an incre-
ment by 6 UI in 1-month survival was observed among
total stages III–IV cancer patients. For the subgroup of
resected patients, a significant survival increase was only
observed for stages I–II cancer patients in the USA (2 UI).
Improvements in 3-month survival were generally larger
and also significant among total patients in the USA and
the Netherlands, with 4 and 6 UI in stages I–II and 3 and 3
UI in stages III–IV cancers, respectively. In Norway, an in-
crement by 6 UI was observed in patients with stages I–II
cancer. In Slovenia, a significant increasing trend by 8 UI
persisted in stages III–IV cancers. Within the resected sub-
group, significant increasing trends were observed in both
stages I–II (2 UI) and III–IV cancer patients (7 UI) in the
USA, and in patients with stages III–IV cancer (10 UI) in
Slovenia.
Longer-term survival
While in all countries 1-year survival increased for pa-
tients with stages I–II PaC, increases were only signifi-
cant in the USA (6 UI), the Netherlands (12 UI), and
Norway (10 UI). For the subgroup of resected patients,
again 1-year survival increased in all countries, but
changes were only significant in the USA (5 UI) and
Norway (11 UI). For overall stages III–IV patients, 1-year
survival increased significantly in the USA (3 UI), the
Netherlands (1 UI), Norway (2 UI), and Slovenia (6 UI).
For resected stages III–IV PaC patients, significant
increases were only observed in the USA (13 UI). Im-
provements in 3-year survival for total stages I–II PaC
patients were generally smaller and significant in the
USA (4 UI), the Netherlands (8 UI), and Norway (2 UI).
For the subgroup of resected stages I–II patients, sig-
nificant increases were observed in the USA (5 UI), the
Netherlands (11 UI), and Belgium (5 UI). Changes in
3-year survival for stages III–IV PaC were minor and
significant only in the USA (< 1 UI) and the Netherlands
(< 1 UI). Significant changes for the subgroup of resected
stages III–IV PaC patients were observed only in the USA
(5 UI). Regarding 5-year survival, significant increases
were observed only in patients with stages I–II cancers.
Survival rates increased by 6 and 1 UI in the Netherlands
and Norway, respectively, for overall patients, and by 8 UI
in the Netherlands for the resected patients.
Discussion
This comprehensive, multinational, large-scale, population-
based investigation provided overall survival estimates for
overall patients and those with resected PaC by TNM stage
and age. Furthermore, temporal trends for overall and
resected cancer patients with clearly resectable (stages
I–II) nd mostly unresectable (stages III–IV) PaCs in
four European countries and the USA were shown re-
spectively. In both stages I–II and III–IV tumors, sur-
vival rates decreased obviously with increasing age.
Limited but encouraging progress in survival over time
was detected.
According to EUROCARE-5 [4, 14], overall, the 1-, 3-,
and 5-year survival rates of patients with PaC diagnosed
during 1999–2007 in Europe were only 26%, 9%, and
7%, respectively. For the European countries investigated
in this study, the 1-year survival was 19–34% and 5-year
survival was 4–11%. In the USA, 5-year survival was 7–
10% [16, 17]. Stage- and treatment-specific survival was
not provided by the previous reports [4, 14]. Our study
provided more up-to-date estimates by including pa-
tients diagnosed during 2003–2014 and further showed
survival by TNM stage and age. Survival decreased with
advancing stage and age. It is important to provide
stratified survival for clinical counseling.
Guidelines [7–11] state that localized PaCs (stages I–II)
are mostly resectable, while T4/stage III and M1/stage IV
diseases are largely unresectable. Our results showed that
resected patients with stages I–II PaCs had higher survival
estimates in all age groups compared to the commonly re-
ported and widely available overall ones. For example,
resected patients < 60 years had 3–19%, 1–13%, and 1–9%
units higher 1-, 3-, and 5-year survival than overall across
countries, respectively. These differences may reflect ef-
fects of both resection and selection of fitter patients for
resection. Given that most patients would perceive a
general PaC prognosis as dismal and thus feel extremely
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distressed, also generating great burdens to their care-
givers, it would be important to show them the objective
survival data, especially for the resected patients, poten-
tially rebuilding hope of life.
Survival in patients with stages III–IV PaCs, the ma-
jority of the diagnosed cases, was much poorer than that
in those with stages I–II tumors, especially in the long
term. In locally advanced PaC, the average overall survival
remains < 1 year [18], and in metastatic tumors, the me-
dian survival is < 6 months [19], with 5-year survival of
only ~ 2% [5]. We showed that even for those < 60 years,
the overall 3- and 5-year survival was as low as 2–5% and
1–4%, respectively. Most patients with stages III–IV PaCs
are deemed unresectable [9, 11]. This may, however, im-
prove in the years to come with the increasing use of
FOLFIRINOX [20]. In many of the cases where patients
with metastatic PaC underwent resection, the metastasis
was unexpectedly detected only during surgery [21]. Al-
though resection rates in advanced tumors were low, not-
ably, in stages III–IV PaCs substantially higher survival
was observed for resected compared to total patients in all
age groups, and resected patients < 70 years could have a
3-year survival of 5–34%. Even in those ≥ 70 years old,
higher survival estimates for the resected subgroup were
observed (1-year, 16–42% vs. 5–14%; 3-year, 2–14% vs.
1%–1%). While this difference might again at least partly
reflect patient selection, i.e., inclusion of healthier patients
or those with more favorable tumor characteristics for re-
section, our results indicated that not all patients with
stages III–IV PaC had such a dismal prognosis as sug-
gested by the overall survival estimates. These strong dif-
ferences again underline the importance of reporting
respective outcomes for stratified resected patients for en-
hanced counseling of these patients.
The perioperative survival is noteworthy, especially for
elderly patients. It is volume-dependent, and is mainly
influenced by failure to rescue and surgical expertise
[22]. While resection could be safely performed for some
proportion of the typically more vulnerable elderly pa-
tients [23, 24], at the population level, we found that in
stages III–IV PaCs, which are associated with poorer gen-
eral status, the 1-month survival dropped from 94–99%
for patients < 70 years to 81–96% for those ≥ 70 years,
which was more dramatic compared to results for the
stages I–II disease. Age was negatively associated with sur-
vival, necessitating it as a stratification factor when provid-
ing survival information. Increasing ages are associated
with more frequent comorbidities and complications, de-
creasing the potential survival benefits of resection. How-
ever, some studies suggested that, compared to younger
individuals, fit elderly patients might obtain similar sur-
vival benefits from resection [23, 24]. The better survival
observed for the younger patients might be partly ex-
plained by the more aggressive therapeutic strategies
applied, which might contribute to survival improvements
in the fit elderly as well [4]. These possibilities highlight
the importance of geriatric assessment before treatment.
No substantial survival changes (5-year, 5–6%) were
reported in PaC in the EUROCARE-5 study [4] over the
period 1999–2007. In the USA, 5-year survival improved
from 6 to 8% between 1992 and 1996 and 2002–2006
[25] and from 8 to 12% between 2002 and 2004 and
2008–2010 [16]; especially for localized tumors, strong
improvement in 5-year survival by 7% units from 1998
to 2003 was observed [17]. We observed modest but
nevertheless encouraging improvements in survival in
patients both with stages I–II and III–IV tumors from
2003 to 2005 to 2009–2011, which potentially reflects
the advancement in surgical skill, technique, and peri-
operative care. In the USA, 3-year survival increased by
4% units in stages I–II PaCs overall, but only by < 1%
units in stages III–IV cancers. For resected cancers, sur-
vival increased by 5% units among patients with stages
I–II cancer. In Europe, 3-year survival for both overall
and resected patients with stages I–II PaC increased in
all investigated countries, and a large increment was ob-
served in the Netherlands (overall, 8% units; resected,
11% units), where postoperative mortality is decreasing
[26]. Notably, centralization agreements were imple-
mented in the Netherlands since 2005, and promoted
more resections [27], which might be associated with
the continuous improvement in survival [28]. While fur-
ther major survival advancement in resected patients
could be limited even with surgical technique modifica-
tion, improved outcomes are likely to come from more
effective systemic treatments (e.g., FOLFIRINOX) com-
bined with surgery. The different trends between overall
and resected patients further highlight the need to offer
survival data in specific subgroups.
This study covered the periods when the sixth and
seventh TNM staging systems were in effect, and both
are compatible/identical with each other [8]. While poten-
tially improved imaging might result in a shift in stage
classification, the proportions of each stage remained rela-
tively stable in investigated countries (data not shown). In
the era of the eighth TNM staging, where the definitions
of the T4 and M1 categories indicating mostly unresect-
able cancers remain unchanged [29], our results would
still be usable for prognosis counseling.
This study was limited by the small case numbers in
some subgroups. Further potentially prognostically import-
ant factors (e.g., comorbidity) were not considered because
they were unknown/unavailable in the national registries of
most countries. Although older ages and more advanced
tumor stages herein investigated were the most prominent
negative prognostic factors and might contraindicate resec-
tion, precise and personalized factors should be considered
for evaluation of an individual patient’s prognosis. Some
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prognostic tools (e.g., the nomogram) might offer more
precise prognostic information for a specific patient. Non-
surgical treatment was not incorporated considering the
low sensitivity in recording in some registries and the vary-
ing regimens used. Information from more countries would
increase the comprehensiveness of the report. However,
treatment or TNM staging data were mostly not readily
available in the other national population-based registries.
Our study was based on complete-case analysis. Differences
in data recording, especially of TNM stage, should be
noted, and the stages I–II cancer proportion varied from
25% in Norway and Slovenia to 38% in Belgium. There
could be underreporting, especially of advanced-stage dis-
ease, with various extents, besides the potential impact of
missing staging information. These differences highlight the
need for standardization in the registration practice. Poten-
tial variation in registration practice, especially for stage,
might affect outcomes, and inter-country comparisons were
not made considering the possible heterogeneity. Results
were only analyzed and interpreted independently in the re-
spective country without pooling or comparison with other
countries. Results from a specific national registry might
not be generalizable to another country. For counseling of
patients not in the studied countries, other aspects includ-
ing treatment profiles and health care systems should be
considered.
In the main analyses, we included PaC cases irre-
spective of microscopic confirmation, which is in ac-
cordance with the real-world situation [15] and which
is also consistent with the approach in the EUROCARE
studies [4, 14]. While resected cases were mostly micro-
scopically confirmed, the confirmation rates for overall
cases varied. The microscopic confirmation rates for PaC
have been relatively low [4], and PaC has always been diffi-
cult to verify microscopically, especially unresectable PaC.
In our complete-case study inclusion of patients with
known stage might have an impact on the observed con-
firmation rates. After limiting the overall cases to the
microscopically confirmed ones in sensitivity analyses, the
survival estimates mostly became higher in all participating
countries except in Belgium, where microscopic confirm-
ation rates were high. Furthermore, the survival increase
was the most prominent in patients ≥ 70 years old, who are
generally more frail and for whom the selection of treat-
ment is usually more cautious. While including microscop-
ically confirmed cases only could help to further increase
the chance of selecting real PaC patients, those not receiv-
ing any treatment and usually having poorer patient and/or
tumor characteristics might be more likely excluded, po-
tentially partly explaining the higher observed survival esti-
mates in the sensitivity analyses.
We showed that it is important to provide survival es-
timates separately to resected patients for counseling, as
the resected subgroup has substantially higher survival
than the overall estimation. We did not show the results
for unresected PaC patients and avoided direct compari-
sons between the resected and the unresected, as they may
to a large extent reflect selection effects related to factors
including patients’ health status and hospital characteris-
tics. In the resected subgroup, curative and palliative resec-
tions were not differentiated from each other, considering
the greatly geographically and temporally varying standards
for defining clear resection margins in PaC surgery.
Nevertheless, the multinational, population-based, large-
scale character of this study with the country-specific re-
spective analysis adds important novel survival data to the
literature. In particular, results stratified by TNM stage and
age for resected and overall patients will further aid patient
counseling in clinical practice, providing more specific sur-
vival information for specific patient populations.
Conclusions
Our international population-based study provides com-
prehensive data on survival expectations of resected PaC
patients which are substantially higher than the widely
available and known dismal survival prognosis for total
patients. The benefits of resection cannot be concluded
from this observational study. However, the TNM stage-
and age-stratified survival results might be helpful for
clinical counseling. Estimated survival for advanced-stage
disease should be interpreted with caution due to poten-
tial underreporting. Patients with advanced stage and/or
old age should undergo careful assessment. Limited but
encouraging survival improvement is observed.
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